Concepedia

Fadi Asfour

FA

13

Publications

750

Citations

11

H-Index

2013

Active since

Affiliations

University of Utah(Current)

Primary Children's Hospital

Indiana University – Purdue University Indianapolis

Intermountain Healthcare

Seattle Children's Hospital

Fadi Asfour is an author at University of Utah specializing in diagnosis, clinical epidemiology, and epidemiology.

ORCID

Top concepts

Publications per year

2013–2023

13

Publications

13

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

, ,

Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways

Ryan C. Hunter, Fadi Asfour, Jozef Dingemans et al. · mBio · 2013 · 167 citations · Full text

Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Nicole Mayer-Hamblett, George Retsch‐Bogart, Margaret Kloster et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 96 citations · Full text

Impact of pharmacy services on cystic fibrosis medication adherence

Jeffery T. Zobell, Elizabeth Schwab, Dave S. Collingridge et al. · Pediatric Pulmonology · 2017 · 33 citations

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>

Jonathan H. Rayment, Fadi Asfour, Margaret Rosenfeld et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 32 citations · Full text

Rows per page

1–5 of 13